CPX-351 Real World Effectiveness and Safety Study (CREST UK) is a real-world evidence study designed to collect data on the potential benefits and/or risks of Vyxeos liposomal (liposomal daunorubicin/cytarabine; CPX-351) in routine clinical practice in the United Kingdom (UK).

This is a retrospective, non interventional, multi-centre, single arm, observational study designed to assess patients with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or acute myeloid leukaemia with myelodysplasia related changes (AML-MRC) who have been treated with Vyxeos liposomal (liposomal daunorubicin/cytarabine; CPX-351) in routine UK clinical practice and managed as per standard local practice.

Inclusion Criteria:

• Aged ≥18 years at the start of treatment of AML with Vyxeos liposomal
• Pathological diagnosis of t-AML or AML-MRC according to World Health Organization criteria (with at least 20% blasts in the peripheral blood or bone marrow)
• Patient has received at least one infusion of Vyxeos liposomal, prescribed as per the SmPC
• Patient signs an informed consent form or is included in accordance with an informed consent waiver

Exclusion Criteria:

• Treatment with Vyxeos liposomal as part of a clinical trial or managed access program
• Prior treatment intended for induction therapy of AML; only hydroxyurea is permitted for control of blood counts

Patients with newly diagnosed, t-AML or AML-MRC who have been treated with Vyxeos liposomal in routine UK clinical practice and managed as per standard local practice will be enrolled in the study.